124 related articles for article (PubMed ID: 7533365)
21. Glucose metabolism following liver transplantation and immunosuppression with cyclosporine A or FK 506.
Senninger N; Golling M; Datsis K; Sido B; Herfarth C; Otto G
Transplant Proc; 1995 Feb; 27(1):1127-8. PubMed ID: 7533364
[No Abstract] [Full Text] [Related]
22. Rejection: FK 506 for rescue or maintenance.
Klintmalm GB; Gibbs JF; McMillan R; Backman L; Levy M; Goldstein RM; Husberg BS; Holman MJ; Gonwa TA
Transplant Proc; 1993 Apr; 25(2):1914-5. PubMed ID: 7682356
[No Abstract] [Full Text] [Related]
23. FK 506 improves recovery of bile secretion following orthotopic liver transplantation in man.
Söderdahl G; Groth CG; Angelin B; Duraj F; Einarsson K; Ericzon BG
Transplant Proc; 1995 Feb; 27(1):1125. PubMed ID: 7533362
[No Abstract] [Full Text] [Related]
24. Normal and gestational diabetic pregnancies. Lipids, lipoproteins and apolipoproteins.
de Arcos F; Castelo-Branco C; Casals E; Sanllehy C; Cararach V
J Reprod Med; 1998 Feb; 43(2):144-8. PubMed ID: 9513877
[TBL] [Abstract][Full Text] [Related]
25. Conversion from cyclosporine to tacrolimus in hepatic and renal transplantation.
Yussim A; Shaharabani E; Mor E; Lustig S; Bar-Nathan N; Shmueli D; Sobolev V; Dorfman B; Or H; Shapira Z
Transplant Proc; 1996 Dec; 28(6):3178-9. PubMed ID: 8962233
[No Abstract] [Full Text] [Related]
26. Serum lipid changes in liver transplantation: effect of steroids withdrawn in a prospective randomized trial under cyclosporine A therapy.
De Carlis L; Belli LS; Colella G; Rondinara GF; Slim AO; Alberti A; Aseni P; Sansalone CV; Pirotta V; Di Benedetto F; Forti D
Transplant Proc; 1999; 31(1-2):391-3. PubMed ID: 10083156
[No Abstract] [Full Text] [Related]
27. FK 506 treatment of intractable rejection after liver transplantation.
Jost U; Winkler M; Ringe B; Rodeck B; Pichlmayr R
Transplant Proc; 1993 Aug; 25(4):2686-7. PubMed ID: 7689276
[No Abstract] [Full Text] [Related]
28. Japanese multicenter studies of FK 506 in renal transplantation. Japanese FK 506 Study Group.
Ochiai T; Ishibashi M; Fukao K; Takahashi K; Endo T; Yokoyama I; Uchida K; Ohshima S; Takahara S; Morozumi K
Transplant Proc; 1995 Feb; 27(1):50-3. PubMed ID: 7533419
[No Abstract] [Full Text] [Related]
29. Nephrotoxicity of FK 506 and cyclosporine when used as primary immunosuppression in liver transplant recipients.
Porayko MK; Textor SC; Krom RA; Hay JE; Gores GJ; Wahlstrom HE; Sanchez-Urdazpal L; Richards T; Crotty P; Beaver S
Transplant Proc; 1993 Feb; 25(1 Pt 1):665-8. PubMed ID: 7679835
[No Abstract] [Full Text] [Related]
30. Tacrolimus (FK 506) therapy is associated with a significant reduction in immunosuppressive treatment failures following primary liver transplantation.
Bechstein WO; Neuhaus P; McMaster P; Calne R; Pichlmayr R; Otto G; Williams R; Ericzon BG; Bismuth H
Transplant Proc; 1996 Apr; 28(2):1008-10. PubMed ID: 8623211
[No Abstract] [Full Text] [Related]
31. Cholesterol levels long-term after liver transplant.
Atillasoy E; Gurkan A; Mor E; Altaca G; Sheiner P; Guy S; Schwartz M; Miller C; Berk P; Emre S
Transplant Proc; 1998 Aug; 30(5):2049-50. PubMed ID: 9723387
[No Abstract] [Full Text] [Related]
32. Effect of CsA versus FK 506 on insulin sensitivity and insulin response using a modeling technique.
Steinmueller T; Konrad T; Vicini P; Toffolo G; Jonas S; Tullius S; Bechstein WO; Cobelli C; Usadel KH; Neuhaus P
Transplant Proc; 1998 Jun; 30(4):1452-3. PubMed ID: 9636589
[No Abstract] [Full Text] [Related]
33. Metabolic effects of cyclosporin A and FK 506 in liver transplant recipients.
Krentz AJ; Dousset B; Mayer D; McMaster P; Buckels J; Cramb R; Smith JM; Nattrass M
Diabetes; 1993 Dec; 42(12):1753-9. PubMed ID: 7694879
[TBL] [Abstract][Full Text] [Related]
34. Randomized trial in primary liver transplantation under immunosuppression with FK 506 or cyclosporine.
Fung J; Todo S; Abu-Elmagd K; Jain A; Tzakis A; Martin M; Selby R; Bronsther O; Doyle H; Gayowski T
Transplant Proc; 1993 Feb; 25(1 Pt 2):1130. PubMed ID: 7680146
[No Abstract] [Full Text] [Related]
35. CMV infection in liver transplantation under cyclosporine or FK 506 immunosuppression.
Alessiani M; Kusne S; Fung JJ; Torre-Cisneros J; Jain A; Abu-Elmagd K; Takaya S; Cillo U; Martin M; Todo S
Transplant Proc; 1991 Dec; 23(6):3035-7. PubMed ID: 1721351
[No Abstract] [Full Text] [Related]
36. Whole-blood and plasma levels of FK 506 after liver transplantation: results from the US Multicenter Trial. FK506 Multicenter Study Group.
Bäckman L; Levy MF; Klintmalm G
Transplant Proc; 1995 Feb; 27(1):1124. PubMed ID: 7533361
[No Abstract] [Full Text] [Related]
37. [Study of serum lipids in normal persons and patients with essential hypertension with reference to carbohydrate metabolism].
Lüthy R
Praxis; 1969 Oct; 58(43):1365-72 contd. PubMed ID: 5395158
[No Abstract] [Full Text] [Related]
38. Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation: long-term results.
Pratschke J; Neuhaus R; Tullius SG; Jonas S; Bechstein WO; Neuhaus P
Transplant Proc; 1998 Jun; 30(4):1419-21. PubMed ID: 9636575
[No Abstract] [Full Text] [Related]
39. Prevalence of dyslipidemia in liver transplant recipients.
Mathe D; Adam R; Malmendier C; Gigou M; Lontie JF; Dubois D; Martin C; Bismuth H; Jacotot B
Transplantation; 1992 Jul; 54(1):167-70. PubMed ID: 1631928
[No Abstract] [Full Text] [Related]
40. [To the dependences between glucose tolerance and serum lipid concentration (author's transl)].
Knubbmann R; Toeller M
Offentl Gesundheitswes; 1973 Sep; 35(9):497-500. PubMed ID: 4271388
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
